Mathai Mammen, SVP, Research & Early Clin Development at THERAVANCE INC (THRX), sold 12,002 shares at $22.14 ($266K) on 2013-02-20, disclosed to the SEC on 2013-02-22.
Scheduled sale ($266k) by SVP, Research & Early Clin Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.10 | 5,002 | $111K | 41.6% |
| 2 | $22.14 | 7,000 | $155K | 58.4% |
| Total | $22.12 avg | 12,002 | $266K | 100% |
| Filing → |
| THRX | SELL | 2013-08-01 | $256K | — | Filing → |
| THRX | SELL | 2013-05-02 | $236K | — | Filing → |
| THRX | SELL | 2012-11-06 | $150K | — | Filing → |